Pegylated liposomal doxorubicin in recurrent malignant glioma: Analysis of a case series

被引:23
作者
Glas, Martin [1 ,2 ]
Koch, Horst [2 ]
Hirschmann, Birgit [2 ]
Jauch, Tanja [2 ]
Steinbrecher, Andreas [2 ]
Herrlinger, Ulrich
Bogdahn, Ulrich [1 ,2 ]
Hau, Peter [2 ]
机构
[1] Univ Bonn, Dept Neurol, Clin Neurooncol Unit, DE-53105 Bonn, Germany
[2] Univ Regensburg, Dept Neurol, Regensburg, Germany
关键词
malignant glioma; anaplastic astrocytoma; glioblastoma; pegylated liposomal doxorubicin; temozolomide;
D O I
10.1159/000113052
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Recurrent malignant glioma has a dismal prognosis, and therapeutic options are scarce. After previous potentially encouraging reports on liposomal pegylated doxorubicin (PEG-DOX) in this setting, PEG-DOX was applied to patients with recurrent malignant glioma in an institutional series. Methods: In a retrospective analysis, 49 patients with recurrent high-grade glioma (WHO III, n = 18; WHO IV, n = 31) were treated with PEG-DOX (days 1 and 14/28, 20 mg/m(2), n = 26) alone or in combination with temozolomide (days 1-5/28, 200 mg/m(2), n = 23). The response rate, progression-free survival and overall survival were evaluated. Results: The rate of progression-free patients at 6 months after initiation of therapy was 27% (WHO III, 33%; WHO IV, 23%). The median overall survival (mOS) after initiation of PEG-DOX (monotherapy and combination therapy) was 8 months (WHO III, 16 months; WHO IV, 7 months). The mOS after initiation of PEG-DOX monotherapy was 8 months, and after initiation of combination therapy, 10 months. Both regimens were well tolerated, with the main side effect being hematologic toxicity (grade 1-2, 8%; grade 3-4, 18%). Conclusion: These data demonstrate the safety and moderate efficacy of PEG-DOX +/- temozolomide therapy in recurrent malignant glioma. The potential of this nonalkylating chemotherapy should be further explored. Copyright (C) 2008 S. Karger AG, Basel.
引用
收藏
页码:302 / 307
页数:6
相关论文
共 17 条
[1]  
Afra D, 2002, LANCET, V359, P1011
[2]   Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse [J].
Brada, M ;
Hoang-Xuan, K ;
Rampling, R ;
Dietrich, PY ;
Dirix, LY ;
Macdonald, D ;
Heimans, JJ ;
Zonnenberg, BA ;
Bravo-Marques, JM ;
Henriksson, R ;
Stupp, R ;
Yue, N ;
Bruner, J ;
Dugan, M ;
Rao, S ;
Zaknoen, S .
ANNALS OF ONCOLOGY, 2001, 12 (02) :259-266
[3]  
BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO
[4]  
2-2
[5]   Temozolomide in the treatment of recurrent malignant glioma [J].
Chang, SM ;
Theodosopoulos, P ;
Lamborn, K ;
Malec, M ;
Rabbitt, J ;
Page, M ;
Prados, MD .
CANCER, 2004, 100 (03) :605-611
[6]   Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme [J].
Chua, SL ;
Rosenthal, MA ;
Wong, SS ;
Ashley, DM ;
Woods, AM ;
Dowling, A ;
Cher, LM .
NEURO-ONCOLOGY, 2004, 6 (01) :38-43
[7]  
Fabel K, 2001, CANCER, V92, P1936, DOI 10.1002/1097-0142(20011001)92:7<1936::AID-CNCR1712>3.0.CO
[8]  
2-H
[9]   Salvage therapy in patients with glioblastoma -: Is there any benefit? [J].
Hau, P ;
Baumgart, U ;
Pfeifer, K ;
Bock, A ;
Jauch, T ;
Dietrich, J ;
Fabel, K ;
Grauer, O ;
Wismeth, C ;
Klinkhammer-Schalke, M ;
Allgäuer, M ;
Schuierer, G ;
Koch, H ;
Schlaier, J ;
Brawanski, A ;
Bogdahn, U ;
Steinbrecher, A .
CANCER, 2003, 98 (12) :2678-2686
[10]   Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma [J].
Hau, P ;
Fabel, K ;
Baumgart, U ;
Rümmele, P ;
Grauer, O ;
Bock, A ;
Dietmaier, C ;
Dietmaier, W ;
Dietrich, J ;
Dudel, C ;
Hübner, F ;
Jauch, T ;
Drechsel, E ;
Kleiter, I ;
Wismeth, G ;
Zellner, A ;
Brawanski, A ;
Steinbrecher, A ;
Marienhagen, J ;
Bogdahn, U .
CANCER, 2004, 100 (06) :1199-1207